Navigation Links
Triptorelin in Medical News

Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA

...nical trials, the most common adverse events occurring in patients were hot flushes, skeletal pain, impotence and headache. As with all LHRH agonists, triptorelin causes an initial transient increase in testosterone levels and may initiate or worsen symptoms during this transient period. Rare post-marketing repo...

Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer

...nical trials, the most common adverse events occurring in patients were hot flushes, skeletal pain, impotence and headache. As with all LHRH agonists, triptorelin causes an initial transient increase in testosterone levels and may initiate or worsen symptoms during this transient period. Rare post-marketing repo...

Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer

...NDA for the 6 month formulation of Trelstar(R) is supported by data from a phase III study on the efficacy and safety of two consecutive injections of triptorelin 6-month formulation in 120 patients with advanced prostate cancer. The results showed that 97.5% of patients achieved castrate levels of serum testost...

Did Medicare Reimbursement Changes Affect Prostate Cancer Treatment?

...e testosterone, and a less noticeable increase in surgery, which accomplishes the same thing," he said. The use of only one of the LHRH agonists -- triptorelin -- increased after the Medicare reimbursement policy changed, the study said. It was the only drug in the class whose reimbursement rate was not chang...

Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories

...in excess of $2.6 billion in 2006. For more information on Debiopharm Group, please visit: http://www.debiopharm.com . (1) This agreement refers to triptorelin formulations mainly sold as Decapeptyl(R), Diphereline(R), and Pamorelin(R) (2) Current Good Manufacturing Practices For further information Ipse...
Triptorelin in Medical Technology

Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients

...phase III study on the efficacy and safety of two consecutive injections of triptorelin 6-month formulation in 120 patients with advanced prostate cancer. The resu... of the 1- and 3-month formulations of triptorelin. About Decapeptyl(R) triptorelin was licensed-in from Tulane University in 1982. Debiopharm developed and su...

Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder

...nical trials, the most common adverse events occurring in patients were hot flushes, skeletal pain, impotence and headache. As with all LHRH agonists, triptorelin causes an initial transient increase in testosterone levels and may initiate or worsen symptoms during this transient period. Rare post-marketing repo...

Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer

...ficacy and safety of two consecutive injections of triptorelin 6-month formulation in 120 patients with advanced ...se event profile of the new 6-month formulation of triptorelin is fully comparable to that observed with the 1- a...ebiopharm S.A. About Decapeptyl(R)/Trelstar(R) triptorelin was licensed-in from Tulane University in 1982. De...

Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration

...udy for its investigational 4-month formulation of triptorelin do not support the expected sustainable blood levels of triptorelin for a duration of 4 months in all patients. Theref...'s new sustained release formulation candidates of triptorelin using one amongst several Ipsen proprietary techno...
Triptorelin in Biological Technology

Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations

...nt, triptorelin, over a period of eight months to seven years in male patients with sexual deviations demonstrated a good efficacy and safety profile. triptorelin produced reversible serum castrate testosterone levels (defined as less than or equal to 1.735 nmol/L) in all patients, and concurrently with the decr...

FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceutical's TRELSTAR(R) DEPOT and TRELSTAR(R) LA

...nical trials, the most common adverse events occurring in patients were hot flushes, skeletal pain, impotence and headache. As with all LHRH agonists, triptorelin causes an initial transient increase in testosterone levels and may initiate or worsen symptoms during this transient period. Rare post-marketing repo...
Other Tags
(Date:7/31/2015)... , ... July 31, 2015 , ... When the weather ... Super-Sod debuted their new type of sod called Leisure Time(TM) zoysia . It's ... process. , To commemorate introduction of this new type of sod, Super-Sod is giving ...
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New ... It was also the first provider of Exilis non-surgical fat reduction in New ... procedures it has attracted a large International clientele. Many patients travel to New ...
(Date:7/31/2015)... Atlanta, GA (PRWEB) , ... July 31, 2015 , ... ... CoolSculpting , the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator ... FDA in January 2014 for treating the outer thighs. The original applicator required ...
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today ... media, and VIPs at the 2015 Vans US Open of Surfing, July 25 through ... can claim “no added sugar” on the market, is a natural choice given the ...
(Date:7/31/2015)... , ... July 31, 2015 , ... According to an ... experts gathered to see if they could reach a consensus on the steps that ... and facelifts. Overall, the group reached 90 percent consensus on a series of steps ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
Other Contents